Of BRAFV600ETwenty-eight melanomas and 15 control nevi were stained with the

Of BRAFV600ETwenty-eight melanomas and 15 control nevi were stained with the BRAFV600E-mutation specific antibody VE1. Immunohistochemistry Anlotinib detected all Tunicamycin web mutations found by Sanger sequencing (Figure 1 D ). In 6 (5.1 ) of 117 tumor-samples (5 melanomas and 1 associated nevus) immunohistochemistry showed a BRAFV600E mutation not detectable by sequencing. These cases remained discordant after repeated microdissection, amplification and sequencing. While no associated nevus showed strong staining, 10.0 (n=2) of melanomas were strongly positive by immunohistochemistry. The majority of associated nevi (80.0 , n=16) stained weakly as did only 25.0 (n=5) of melanomas. Twenty percent (n=4) of associated nevi and 65.0 (n=13) of melanomas showed an intermediate staining intensity. Paired analysis revealed that melanomas showed a stronger immunohistochemical staining intensity than their associated nevi (Wilcoxon signed-rank test, p=0.002) (Figure 1 C,D,F and Figures S2 S3 H,I).Frequency of BRAF/NRAS mutations detected by Sanger sequencingNRAS-mutations within Exon 2 were found in 11.9 (n=5), 18.2 (n=8) and 14.3 (n=3) of melanomas, associated nevi and control nevi, respectively. All non-silent mutations were substitutions of the Codon 61 (Q61K, Q61L or Q61R; Table 1). BRAFV600-mutations within exon 15 detected by Sangersequencing were present in 51.1 (n=23), 63.0 (n=29) and 52.0 (n=13) in melanomas, associated nevi and control nevi, respectively. With the exception 18204824 of a single 1315463 V600K substitution in a control nevus, all mutations within Codon 600 were an exchange of Valine by Glutamine (V600E) (Table 1). Four mutations in four different patients outside Codon 600 were detected: S602F (melanoma), S607F (associated nevus), R603Q (control nevus) and one single nucleotide variant withinBRAF and NRAS mutations in control nevi, melanomas and associated neviThe frequency of oncogenic mutations did not differ significantly between melanoma-associated nevi and controlnevi or between melanomas and their associated nevi (Figures 2 and S4). However, in four pairs a BRAF-wildtype nevus wasNRAS and BRAF in Melanoma-Associated NeviTable 2. Comparison of clinical and morphologic criteria between nevi groups.p-value Associated Nevus (n=46) Morphology Bridging Lentiginous / epitheloid cell proliferation Fibroplasia Cytologic atypia Nevus subtype Mutations Junctional component NRASQ61 BRAF VE1) Anatomic Site TrunkVControl 20.0 (n=5) 68.0 (n=17) 52.0 (n=13) 40.0 (n=10) 92.0 (n=23) 14.3 (n=3) 52.0 (n=13) 56.1 (n=14)(Chi-Nevus (n=25)square) 0.2.2 (n=1)10.9 (n=5)<0.4.3 (n=2) 13.0 (n=6) 15.2 (n=7) 15.9 (n=7)<0.001 0.009 <0.001 1.000 0.217 0.(Seq65.2 (n=30) 76.1 (n=35)status was not associated with a age, gender or invasion thickness.BRAF and NRAS mutations of matched melanomasFor 28 cases (26 for NRAS) a melanoma without an associated nevus, could be matched for patient age ?3 years, gender and anatomic site. Matched melanomas harbored a BRAFV600E mutation in 42.9 (n=12) of cases and NRASQ61 mutations in 7.7 (n=2). The frequency of V600E or Q61 mutations was not different compared to melanomas with associated nevi (p=0.45 and p=0.63 respectively).Figure 1. Melanoma in association with a nevus in overview (A) and closeup (B). . Immunohistochemically stained in (C) with the BRAFV600E-mutation specific antibody VE1. Benign(D) and malignant(F) parts of the tumor in closeup. E G show sequencing result of the corresponding cuts.doi: 10.1371/journal.p.Of BRAFV600ETwenty-eight melanomas and 15 control nevi were stained with the BRAFV600E-mutation specific antibody VE1. Immunohistochemistry detected all mutations found by Sanger sequencing (Figure 1 D ). In 6 (5.1 ) of 117 tumor-samples (5 melanomas and 1 associated nevus) immunohistochemistry showed a BRAFV600E mutation not detectable by sequencing. These cases remained discordant after repeated microdissection, amplification and sequencing. While no associated nevus showed strong staining, 10.0 (n=2) of melanomas were strongly positive by immunohistochemistry. The majority of associated nevi (80.0 , n=16) stained weakly as did only 25.0 (n=5) of melanomas. Twenty percent (n=4) of associated nevi and 65.0 (n=13) of melanomas showed an intermediate staining intensity. Paired analysis revealed that melanomas showed a stronger immunohistochemical staining intensity than their associated nevi (Wilcoxon signed-rank test, p=0.002) (Figure 1 C,D,F and Figures S2 S3 H,I).Frequency of BRAF/NRAS mutations detected by Sanger sequencingNRAS-mutations within Exon 2 were found in 11.9 (n=5), 18.2 (n=8) and 14.3 (n=3) of melanomas, associated nevi and control nevi, respectively. All non-silent mutations were substitutions of the Codon 61 (Q61K, Q61L or Q61R; Table 1). BRAFV600-mutations within exon 15 detected by Sangersequencing were present in 51.1 (n=23), 63.0 (n=29) and 52.0 (n=13) in melanomas, associated nevi and control nevi, respectively. With the exception 18204824 of a single 1315463 V600K substitution in a control nevus, all mutations within Codon 600 were an exchange of Valine by Glutamine (V600E) (Table 1). Four mutations in four different patients outside Codon 600 were detected: S602F (melanoma), S607F (associated nevus), R603Q (control nevus) and one single nucleotide variant withinBRAF and NRAS mutations in control nevi, melanomas and associated neviThe frequency of oncogenic mutations did not differ significantly between melanoma-associated nevi and controlnevi or between melanomas and their associated nevi (Figures 2 and S4). However, in four pairs a BRAF-wildtype nevus wasNRAS and BRAF in Melanoma-Associated NeviTable 2. Comparison of clinical and morphologic criteria between nevi groups.p-value Associated Nevus (n=46) Morphology Bridging Lentiginous / epitheloid cell proliferation Fibroplasia Cytologic atypia Nevus subtype Mutations Junctional component NRASQ61 BRAF VE1) Anatomic Site TrunkVControl 20.0 (n=5) 68.0 (n=17) 52.0 (n=13) 40.0 (n=10) 92.0 (n=23) 14.3 (n=3) 52.0 (n=13) 56.1 (n=14)(Chi-Nevus (n=25)square) 0.2.2 (n=1)10.9 (n=5)<0.4.3 (n=2) 13.0 (n=6) 15.2 (n=7) 15.9 (n=7)<0.001 0.009 <0.001 1.000 0.217 0.(Seq65.2 (n=30) 76.1 (n=35)status was not associated with a age, gender or invasion thickness.BRAF and NRAS mutations of matched melanomasFor 28 cases (26 for NRAS) a melanoma without an associated nevus, could be matched for patient age ?3 years, gender and anatomic site. Matched melanomas harbored a BRAFV600E mutation in 42.9 (n=12) of cases and NRASQ61 mutations in 7.7 (n=2). The frequency of V600E or Q61 mutations was not different compared to melanomas with associated nevi (p=0.45 and p=0.63 respectively).Figure 1. Melanoma in association with a nevus in overview (A) and closeup (B). . Immunohistochemically stained in (C) with the BRAFV600E-mutation specific antibody VE1. Benign(D) and malignant(F) parts of the tumor in closeup. E G show sequencing result of the corresponding cuts.doi: 10.1371/journal.p.